Rxivist logo

Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity

By Joseph J Sabatino, Kristen Mittl, William Rowles, Kira Mcpolin, Jayant Rajan, Colin R. Zamecnik, Ravi Dandekar, Bonny Alvarenga, Rita P Loudermilk, Chloe Gerungan, Collin spencer, Sharon Sagan, Danillo Augusto, Jessa Alexander, Jill A Hollenbach, Michael R Wilson, Scott Zamvil, Riley Bove

Posted 20 Sep 2021
medRxiv DOI: 10.1101/2021.09.10.21262933

Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive understanding of how MS DMTs impact SARS-CoV-2 vaccine responses is lacking. We completed a detailed analysis of SARS-CoV-2 vaccine-elicited spike antigen-specific IgG and T cell responses in a cohort of healthy controls and MS participants in six different treatment categories. Two specific DMT types, sphingosine-1-phosphate (S1P) receptor modulators and anti-CD20 monoclonal antibodies (mAb), resulted in significantly reduced spike-specific IgG responses. Longer duration of anti-CD20 mAb treatment prior to SARS-CoV-2 vaccination were associated with absent antibody responses. Except for reduced CD4+ T cell responses in S1P-treated patients, spike-specific CD4+ and CD8+ T cell reactivity remained robust across all MS treatment types. These findings have important implications for clinical practice guidelines and vaccination recommendations in MS patients and other immunosuppressed populations.

Download data

  • Downloaded 1,125 times
  • Download rankings, all-time:
    • Site-wide: 28,477
    • In neurology: 86
  • Year to date:
    • Site-wide: 14,604
  • Since beginning of last month:
    • Site-wide: 42,318

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide